• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Royalty Pharma Plc Cl A (NQ: RPRX )

    28.39 -0.15 (-0.54%)
    Streaming Delayed Price Updated: 1:20 PM EDT, Jul 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Royalty Pharma Plc Cl A

    < Previous 1 2 Next >
    Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma Declares Third Quarter 2024 Dividend
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
    From Royalty Pharma plc; Cytokinetics
    Via GlobeNewswire
    Royalty Pharma to Present at Upcoming Investor Conferences
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma Reports First Quarter 2024 Results
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma Declares Second Quarter 2024 Dividend
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma Reports Q4 and Full Year 2023 Results
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma Announces Dividend Increase
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
    From Royalty Pharma plc
    Via GlobeNewswire
    Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
    From Teva Pharmaceutical Industries Limited
    Via Business Wire
    Royalty Pharma Reports Third Quarter 2023 Results
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma Declares Fourth Quarter 2023 Dividend
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma Appoints Eric Schneider as Chief Technology Officer
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma to Present at Upcoming Investor Conferences
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg)
    From Royalty Pharma plc
    Via GlobeNewswire
    Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)
    From Ferring Pharmaceuticals
    Via Business Wire
    Royalty Pharma Reports Second Quarter 2023 Results
    From Royalty Pharma plc
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.